(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
The most effective method to Quick Track Your Outcome in Advanced Showcasing with a Web-based Degree - 2Step by step instructions to Lessen Your Gamble of Creating Cellular breakdown in the lungs
- 3Portable Installment Answers for Independent ventures
- 47 Fun Plans to Make Film Evenings Seriously Invigorating (You'll Cherish #5!)
- 5She was moments away from giving birth. The hospital discharged her
- Don’t let food poisoning crash your Thanksgiving dinner
- Ukraine: Russians abduct 50 Ukrainians from border village in Sumy
- Congress is running out of time to extend ACA subsidies as the GOP moves on to an alternative plan. Here's where things stand.
- Mossad unveils network of Hamas terror infrastructure across Europe
- Washington state experiences historic flooding as Skagit River hits record high level. See flooding maps, highway closures and forecasts.
- Trump says Venezuela will start 'turning over' oil to the U.S. Is that the reason he toppled Maduro — or is it something else?
- Major railway disruptions persist as Germany braces for more snow
- Top Pastry: What's Your Sweet Treat of Decision?
- The Best 10 Innovation Developments of the Year
